ClinicalTrials.gg
RecruitingNCT06325202CLEARUpdated Oct 30, 2026

Closed Loop and Education for Hypoglycemia Awareness Restoration

An interventional study of Omnipod 5 or Medtronic 780G and My HypoCOMPaSS Education in Diabetes Mellitus, Type 1, sponsored by Milton S. Hershey Medical Center. Recruiting at 8 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Milton S. Hershey Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Oct 30, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
324
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 190 open to participants now, 257 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.

Planned enrollment
90th of 1,242
324 · median 40
Started
2025
with 64 others
No phase
614 of 1,458
99 open now
Primary completion
2029-12
later than 230 of 256 live
Registered
1,290th of 1,458
by date

Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 90th largest by planned enrollment of the 1,242 interventional ones that give a count, is one of 65 that started in 2025, is one of 614 with no phase, reaches primary completion later than 230 of the 256 other live ones, and was the 1,290th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

190 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:

185 more — sign in →

All 190 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, or all of them as a file.
02

Study summary

The purpose of the CLEAR study is to determine the effect on counterregulatory responses (CRR) of intervening (by attempting to strictly avoid hypoglycemia) to improve awareness of hypoglycemic symptoms among adults with type 1 diabetes (T1D) who have impaired awareness of hypoglycemia (IAH). IAH affects 20-25% of adults with T1D, and rises with increasing duration of T1D.

Read the detailed description

Individuals with IAH exhibit blunted symptomatic and CR hormonal responses to hypoglycemia and, as such, have an impaired ability to respond to hypoglycemia. Thus, rates of severe hypoglycemia are up to 6-fold greater in those affected. Intensive management of T1D is necessary in preventing long-term complications, but can be complicated by recurrent episodes of hypoglycemia which lead to and sustain the CRR deficits of IAH. Technologies such as continuous glucose monitoring (CGM) and hybrid closed-loop (HCL) systems can reduce severe hypoglycemia (and also may reduce IAH) but the ability of technology to reverse impaired CRR (as assessed with experimental hypoglycemia clamp) remains unclear. Behavioral and psycho-educational interventions targeting knowledge/skills gaps, as well as particular cognitions and behaviors driving recurrent hypoglycemia, can also reduce severe hypoglycemia and improve awareness. No studies have compared technology with such behavioral interventions in terms of assessing their impact on IAH or the CRR (as a primary outcome). Unanswered questions include the degree of reduction in hypoglycemia required to restore awareness. Furthermore, participants may respond to different interventions according to their characteristics. For example, it remains unclear whether older individuals benefit from such interventions since they usually are excluded from studies. Therefore, there is an urgent need to determine effective interventions that can reverse IAH in a large representative population of adults with T1D and IAH. The investigators propose to study the effect of specific interventions aimed at restoring

  • the CRR (tested via an experimental hypoglycemia clamp procedure)
  • hypoglycemia awareness (self-reported via the Towler Questionnaire during the experimental hypoglycemia clamp procedure)

The study will use a Sequential Multiple Assignment Randomized Trial (SMART) design. At baseline, all participants who are HCL naïve will be randomized to HCL or Usual Care (UC) plus brief education (My HypoCOMPaSS) with a follow-up of two years. UC will consist of real-time continuous glucose monitoring (CGM) and insulin delivery via pump or multiple daily injections. Participants who fail to increase their CRR at 12 months will be randomized, or assigned, to a second intervention consisting of a small-group educational program focusing on motivations and unhelpful cognitions acting as barriers to hypoglycemia avoidance (HARPdoc). At baseline, all participants who are HCL non-naïve will be randomized to optimized HCL or HCL plus My HypoCOMPaSS; those with non-responsive CRR at 12 months will be randomized to either continue HCL (on the basis they need a longer period to reverse impaired CRR and total symptomatic responses) or to the HARPdoc intervention. Participants randomized to an HCL device are expected to wear the device continually, as well as a CGM. The My HypoCOMPaSS education requires 4-5 hours of training, whereas, the HARPdoc education requires four training sessions of seven hours each during weeks 1,2,3, and 6.

The specific aims and hypotheses are as follows:

Aim 1: To determine the effect on CRR (epinephrine increase ≥ 125 pg/ml over baseline) and total symptom responses (Towler Questionnaire increase ≥ 20% over baseline) during a hyperinsulinemic-hypoglycemic clamp procedure (glucose \< 50 mg/dl) after 12 months of HCL versus Usual Care plus My HypoCOMPaSS Educational Intervention among adults with T1D and IAH who have never used HCL therapy previously.

Hypothesis 1: At 12 months, those allocated to Usual Care plus My HypoCOMPaSS will be more likely to have improved CRR and total symptomatic responses than those allocated to HCL.

Aim 2: To determine the effect on CRR and total symptom responses at 12 months of HCL plus My HypoCOMPaSS versus HCL alone among adults with T1D and IAH who are currently using HCL therapy prior to entering the study.

Hypothesis 2: At 12 months, those allocated to HCL plus My HypoCOMPaSS will be more likely to have improved hypoglycemic awareness and improved CRR than those using HCL alone.

Aim 3: To determine the durability of effect over 24 months of the intervention that improves CRR at 12 months among adults with type 1 diabetes and IAH at baseline.

Hypothesis 3: At 24 months, CRR will improve further among those who had restored CRR at 12 months.

Aim 4. To determine the effect on hypoglycemic awareness (Towler Questionnaire increase ≥ 20% over baseline) and CRR (epinephrine increase ≥ 125 pg/ml over baseline) during a hyperinsulinemic hypoglycemic clamp procedure at 24 months of an in-depth educational program (HARPdoc), initiated throughout months 12-24, among adults with T1D and IAH at baseline, for whom the intervention allocated at baseline did not restore CRR at 12 months.

Hypothesis 4: At 24 months, those allocated to HARPdoc for months 12-24 months will be more likely to have improved hypoglycemic awareness and CRR than those who continue with the therapy allocated at baseline.

03

Conditions studied

  • Diabetes Mellitus, Type 1

Keywords

  • impaired awareness of hypoglycemia
  • hybrid closed loop device
  • continuous glucose monitor
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of type 1 diabetes
  • Gold Score or Clarke Score ≥ 4 (highly associated with IAH)
  • Random non-fasting C-peptide \< 200 pmol/L
  • Diabetes duration ≥ 10 years
  • \< 10.5%
  • Total Daily Insulin Dose of \< 1 unit/kg
  • Ability to read and speak English (because validated non-English versions of the cognitive tests and the educational interventions are not available)

Exclusion criteria

Exclusion Criteria:

  • Medical conditions that limit participation in study activities, as determined by the PI (including but not limited to cognitive dysfunction, reduced hearing, reduced vision, cancer under active treatment, untreated angina, organ failure)
  • Active alcohol or drug abuse (as defined by DSM criteria of either 1) recurrent use of alcohol/drugs resulting in a failure to fulfill major role obligations at work, school, or home, 2) recurrent alcohol/drug use in situations in which it is physically hazardous, or 3) recurrent alcohol or drug-related legal problems)
  • Social determinants of health that limit participation in study activities, as determined by the PI (including but not limited to homelessness, food insecurity, inadequate social support)
  • Seizure disorder unrelated to hypoglycemia associated seizures, unless documented seizure-free for >12 months and on a stable regimen of anti-convulsant therapy
  • Skin conditions that would preclude the use of a CGM
  • Super-physiologic exposure to within one month of enrollment
  • \< 45 mL/min/1.73 m2
  • History of bariatric surgery that irreversibly alters gut innervation and structure
  • Hyper- or hypokalemia (serum potassium >5.5 or \<3.5 mmol/L)*
  • \< 10 g/dL*
  • Medical condition that requires intermittent or continuous use of glucocorticoids at greater than physiological replacement doses
  • Pregnancy, plan for pregnancy, or breast feeding
  • Abnormal thyroid function tests of clinical significance, as determined by PI*
  • Liver transaminases > 3 times the *
  • Hospitalization for mental illness in last year
  • History of adrenalectomy

    • At discretion of the PI, laboratory tests may be repeated once. If the participant is not eligible after the second attempt, then the participant. The participant may be screened again.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
324 participants (estimated)

Study arms

  • Experimental
    current HCL non-user: HCL x 24 months

    Hybrid closed loop device over a 24-month period for individuals currently not using a hybrid closed loop device

    Device: Omnipod 5 or Medtronic 780G

  • Experimental
    current HCL non-user: HCL x 12 months, then HCL x an additional 12 months

    Hybrid closed loop device over a 12-month period for individuals currently not using a hybrid closed loop device, and then a hybrid closed loop device for an additional 12 months

    Device: Omnipod 5 or Medtronic 780G

  • Experimental
    current HCL non-user: HCL x 12 months, then HCL + HARPdoc x 12 months

    Hybrid closed loop device over a 12-month period for individuals currently not using a hybrid closed loop device, then a hybrid closed loop device plus HARPdoc education for an additional 12 months

    Device: Omnipod 5 or Medtronic 780G · Behavioral: HARPdoc Education

  • Active comparator
    current HCL non-user: Usual Care and My HypoCOMPaSS x 12 months, then HCL x 12 months

    Usual Care and My HypoCOMPaSS education over 12 months for individuals currently not using a hybrid closed loop device, then hybrid closed loop device for 12 months

    Device: Omnipod 5 or Medtronic 780G · Behavioral: My HypoCOMPaSS Education

  • Active comparator
    current HCL non-user: Usual Care and My HypoCOMPaSS x 24 months

    Usual Care and My HypoCOMPaSS education over 24 months for individuals currently not using a hybrid closed loop device

    Behavioral: My HypoCOMPaSS Education

  • Experimental
    current HCL user: HCL x 24 months

    Hybrid closed loop device over a 24-month period for individuals currently using a hybrid closed loop device

    Device: Omnipod 5 or Medtronic 780G

  • Experimental
    current HCL user: HCL x 12 months, then HCL x an additional 12 months

    Hybrid closed loop device over a 12-month period for individuals currently using a hybrid closed loop device, and then a hybrid closed loop device for an additional 12 months

    Device: Omnipod 5 or Medtronic 780G

  • Experimental
    current HCL user: HCL x 12 months, then HCL + HARPdoc x 12 months

    Hybrid closed loop device over a 12-month period for individuals currently using a hybrid closed loop device, then a hybrid closed loop device plus HARPdoc education for an additional 12 months

    Device: Omnipod 5 or Medtronic 780G · Behavioral: HARPdoc Education

  • Active comparator
    current HCL user: HCL and My HypoCOMPaSS x 12 months, then HCL x 12 months

    Hybrid closed loop device and My HypoCOMPaSS education over 12 months for individuals currently using a hybrid closed loop device, then hybrid closed loop device for 12 months

    Device: Omnipod 5 or Medtronic 780G · Behavioral: My HypoCOMPaSS Education

  • Active comparator
    current HCL user: HCL + My HypoCOMPaSS x 12 months, then HCL + My HypoCOMPaSS + HARPDOC x 12 months

    Hybrid closed loop device and My HypoCOMPaSS education over 12 months for individuals currently using a hybrid closed loop device, then hybrid closed loop device plus My HypoCOMPaSS eduction + HARPdoc education for 12 months

    Device: Omnipod 5 or Medtronic 780G · Behavioral: My HypoCOMPaSS Education · Behavioral: HARPdoc Education

  • Experimental
    current HCL user: HCL + My HypoCOMPaSS x 24 months

    Hybrid closed loop device plus My HypoCOMPaSS education over a 24-month period for individuals currently using a hybrid closed loop device

    Device: Omnipod 5 or Medtronic 780G · Behavioral: My HypoCOMPaSS Education

Interventions

  • DeviceOmnipod 5 or Medtronic 780G

    Omnipod 5 and Medtronic 780G are hybrid closed loop devices that provide automated insulin delivery.

  • BehavioralMy HypoCOMPaSS Education

    My HypoCOMPaSS is a brief, standardized psycho-educational program delivered in small groups. Facilitated discussions focus on advocating rigorous avoidance of hypoglycemia while maintaining time in target glycemic range.

  • BehavioralHARPdoc Education

    The HARPdoc program targets cognitions around hypoglycemia that act as barriers to hypoglycemia avoidance and recovery of awareness using motivational and cognitive approaches, delivered by diabetes educators, trained and supported by a clinical psychologist, in small group format.

06

What researchers measure

Primary outcomes

  1. epinephrine (pg/ml)

    a change in epinephrine (pg/ml) that exceeds 125 pg/ml between (1) 12 months and baseline, and (2) 24 months and baseline

    Time frame: measured during the clamp studies at 0 (baseline), 12, and 24 months

  2. Towler questionnaire

    the Towler questionnaire consists of 12 questions each on a 0-6 Likert scale; a change in the questionnaire that exceeds 20% between (1) 12 months and baseline, and (2) 24 months and baseline

    Time frame: measured during the clamp studies at 0 (baseline), 12, and 24 months

Secondary outcomes

  1. geometric mean of plasma glucagon

    geometric mean of plasma glucagon

    Time frame: measured during the clamp studies at 0 (baseline), 12, and 24 months

  2. geometric mean of plasma pancreatic polypeptide

    geometric mean of plasma pancreatic polypeptide

    Time frame: measured during the clamp studies at 0 (baseline), 12, and 24 months

  3. geometric mean of plasma free fatty acids

    geometric mean of plasma free fatty acids

    Time frame: measured during the clamp studies at 0 (baseline), 12, and 24 months

  4. glucose infusion rate

    glucose infusion rate

    Time frame: measured during the clamp studies at 0 (baseline), 12, and 24 months

  5. HbA1c

    glycated hemoglobin

    Time frame: measured during the clamp studies at 0 (baseline), 12, and 24 months

  6. % of time with sensor hypoglycemia <70 mg/dL

    % of time with hypoglycemia \<70 mg/dL determined from the continuous glucose monitor (CGM) sensor

    Time frame: measured during the four weeks prior to each clamp study at 0 (baseline), 12, and 24 months

  7. % of time with sensor hypoglycemia <54 mg/dL

    % of time with hypoglycemia \<54 mg/dL determined from the continuous glucose monitor (CGM) sensor

    Time frame: measured during the four weeks prior to each clamp study at 0 (baseline), 12, and 24 months

  8. number of hypoglycemia events

    number of hypoglycemia events determined from the continuous glucose monitor (CGM) sensor

    Time frame: measured during the four weeks prior to each clamp study at 0 (baseline), 12, and 24 months

  9. % time with sensor glucose in range

    % time with glucose in range determined from the continuous glucose monitor (CGM) sensor

    Time frame: measured during the four weeks prior to each clamp study at 0 (baseline), 12, and 24 months

  10. sensor glucose coefficient of variation

    sensor glucose coefficient of variation determined from the continuous glucose monitor (CGM) sensor

    Time frame: measured during the four weeks prior to each clamp study at 0 (baseline), 12, and 24 months

  11. sensor use as the average numbers of days per week

    sensor use as the average number of days per week determined from the continuous glucose monitor (CGM) sensor

    Time frame: measured during the four weeks prior to each clamp study at 0 (baseline), 12, and 24 months

  12. glycemia risk index

    glycemia risk index determined from the continuous glucose monitor (CGM) sensor

    Time frame: measured during the four weeks prior to each clamp study at 0 (baseline), 12, and 24 months

  13. Trail Making Test - Part B

    amount of time required to complete the Trail Making Test - Part B

    Time frame: measured during the clamp studies at 0 (baseline), 12, and 24 months

  14. Four Choice Reaction Time

    Four Choice Reaction Time, which measures reaction time and motor coordination

    Time frame: measured during the clamp studies at 0 (baseline), 12, and 24 months

  15. sleep duration

    sleep duration determined from an activity monitor smartwatch

    Time frame: measured during the two weeks prior to each clamp study at 0 (baseline), 12, and 24 months

  16. sleep quality

    sleep quality determined by an activity monitor smartwatch

    Time frame: measured during the two weeks prior to each clamp study at 0 (baseline), 12, and 24 months

  17. 24-hour step count

    24-hour step count determined by an activity monitor smartwatch

    Time frame: measured during the two weeks prior to each clamp study at 0 (baseline), 12, and 24 months

  18. exercise bouts

    exercise bouts determined by an activity monitor smartwatch

    Time frame: measured during the two weeks prior to each clamp study at 0 (baseline), 12, and 24 months

  19. resting heart rate

    resting heart rate determined by an activity monitor smartwatch

    Time frame: measured during the two weeks prior to each clamp study at 0 (baseline), 12, and 24 months

  20. heart rate during exercise

    heart rate during exercise determined by an activity monitor smartwatch

    Time frame: measured during the two weeks prior to each clamp study at 0 (baseline), 12, and 24 months

  21. heart rate variability

    heart rate variability determined by an activity monitor smartwatch

    Time frame: measured during the two weeks prior to each clamp study at 0 (baseline), 12, and 24 months

  22. Hypo-METRICS questionnaire

    Hypo-METRICS questionnaire, a Person-Reported Outcome Measure (PROM) specific to hypoglycemia

    Time frame: measured two weeks prior to each clamp study at 0 (baseline), 12, and 24 months

  23. Hypoglycemic Confidence Scale

    Hypoglycemic Confidence Scale, a Person-Reported Outcome Measure (PROM) specific to hypoglycemia, the range is 0 through 27 and higher scores correspond to higher confidence

    Time frame: measured two weeks prior to each clamp study at 0 (baseline), 12, and 24 months

  24. Hypoglycemia Fear Survey-II

    Hypoglycemia Fear Survey-II, a Person-Reported Outcome Measure (PROM) specific to hypoglycemia

    Time frame: measured two weeks prior to each clamp study at 0 (baseline), 12, and 24 months

  25. Attitudes to Awareness of Hypoglycaemia

    Attitudes to Awareness of Hypoglycaemia, a Person-Reported Outcome Measure (PROM) specific to hypoglycemia

    Time frame: measured two weeks prior to each clamp study at 0 (baseline), 12, and 24 months

  26. Type 1 Diabetes Distress Scale

    Type 1 Diabetes Distress Scale, a Person-Reported Outcome Measure (PROM) specific to hypoglycemia

    Time frame: measured two weeks prior to each clamp study at 0 (baseline), 12, and 24 months

  27. Diabetes Self-Management Questionnaire

    Diabetes Self-Management Questionnaire, a Person-Reported Outcome Measure (PROM) specific to hypoglycemia

    Time frame: measured two weeks prior to each clamp study at 0 (baseline), 12, and 24 months

  28. Diabetes Management Experiences Questionnaire

    Diabetes Management Experiences Questionnaire, a Person-Reported Outcome Measure (PROM) specific to hypoglycemia

    Time frame: measured two weeks prior to each clamp study at 0 (baseline), 12, and 24 months

  29. PROMIS Sleep Disturbance - Short Form 8a

    PROMIS Sleep Disturbance - Short Form 8a

    Time frame: measured two weeks prior to each clamp study at 0 (baseline), 12, and 24 months

  30. Hospital Anxiety and Depression Scale

    Hospital Anxiety and Depression Scale

    Time frame: measured two weeks prior to each clamp study at 0 (baseline), 12, and 24 months, the range is 0 through 42 and higher scores correspond to higher anxiety and depression

  31. 12-Item Hypoglycemia Impact Profile

    12-Item Hypoglycemia Impact Profile, a Person-Reported Outcome Measure (PROM) specific to hypoglycemia

    Time frame: measured two weeks prior to each clamp study at 0 (baseline), 12, and 24 months

  32. EQ-5D-5L

    EQ-5D-5L, a quality-of-life scale with 5 dimensions

    Time frame: measured two weeks prior to each clamp study at 0 (baseline), 12, and 24 months

  33. device-related adverse events

    device-related adverse events

    Time frame: throughout the duration of the 24 months of follow-up

  34. severe hypoglycemic events, self-reported on a CLEAR data collection form

    severe hypoglycemic events, self-reported on a CLEAR data collection form

    Time frame: throughout the duration of the 24 months of follow-up

  35. diabetic ketoacidosis (DKA) events

    diabetic ketoacidosis (DKA) events

    Time frame: throughout the duration of the 24 months of follow-up

  36. number of participants with hospitalizations

    number of participants with hospitalizations

    Time frame: throughout the duration of the 24 months of follow-up

  37. number of participants with emergency room (ER) visits

    number of participants with emergency room (ER) visits

    Time frame: throughout the duration of the 24 months of follow-up

  38. major adverse cardiovascular events (MACE)

    major adverse cardiovascular events (MACE)

    Time frame: throughout the duration of the 24 months of follow-up

  39. all-cause mortality

    all-cause mortality

    Time frame: throughout the duration of the 24 months of follow-up

07

Study locations

8 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The release data sets will be stored at the NIDDK Central Repository. The release data sets will de-identified, i.e., they will not contain names, social security numbers, addresses, phone numbers, health care records, and/or similar protected health information. In addition, the release data sets will have an anonymous study ID that is linked to an individual only in the participant records at the Biostatistics Research Center at the Penn State College of Medicine.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: The timeline for data sharing from the Impaired Awareness of Hypoglycemia Consortium will meet NIH data sharing requirements, such as one year after the Consortium investigators have published the primary manuscript. The Biostatistics Research Center at the Penn State College of Medicine will make data available after the acceptance for publication of the main findings that address the specific aims of the study.

Access criteria: Investigators external to the Consortium will be able to request the data from the NIDDK Central Repository. They will be required to show proof of their local IRB approval.

Data sharing details ↗ · repository.niddk.nih.gov

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2029, 50 months after the start.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 50 months is above that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Jul 2029 → Dec 2029 and completion Jul 2029 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2024
First posted
Mar 22, 2024
StartActual
Oct 3, 2025
Primary completionEst.
Dec 31, 2029was Jul 2029
CompletionEst.
Dec 31, 2029was Jul 2029
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 31, 2029→Dec 31, 2029
Oct 30, 2026
Study completion
Jul 31, 2029→Dec 31, 2029
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Primary completion Jul 31, 2029→Dec 31, 2029
    Study completion Jul 31, 2029→Dec 31, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06325202
Responsible party
Vernon Michael Chinchilli (Distinguished Professor, Penn State Health Milton S Hershey Medical Center) — Principal investigator
First posted
Mar 22, 2024
Start date
Oct 3, 2025
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Oct 30, 2026

Study contacts

Abid Kazi, PhD
Contact
akazi@pennstatehealth.psu.edu
717-531-0003 ext. 320036
Venus Grella, MPH
Contact
vgrella@pennstatehealth.psu.edu
717-531-0003 ext. 343413
Vernon M Chinchilli, PhD
principal investigator · Penn State College of Medicine
Elizabeth R Seaquist, MD
study chair · University of Minnesota
Simon Heller, MD
study chair · University of Sheffield

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion